Tailored Pain Guide (TPG) Study

Sponsor
University of Michigan (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05843890
Collaborator
(none)
430
1
2
21.1
20.4

Study Details

Study Description

Brief Summary

This research is studying whether changing an individual's behaviors may have an impact as a treatment or outcome for chronic low back pain. This research will try to understand how much an electronic, self-management website like PainGuide can help participants.

The study hypothesizes that tailored digital interventions (plus using PainGuide) will demonstrate greater improvement in pain interference.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Structured and tailored PainGuide
  • Behavioral: Standard PainGuide
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
430 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Tailored Pain Guide (TPG) Study
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Structured and tailored PainGuide

Behavioral: Structured and tailored PainGuide
Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2. Participants will be asked to complete surveys over 24 weeks. All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts).

Active Comparator: Standard PainGuide

Behavioral: Standard PainGuide
Participants in the control group will not receive any messaging once enrolled. Participants will be asked to complete surveys over 24 weeks. All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts).

Outcome Measures

Primary Outcome Measures

  1. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference score [Baseline, Week 24]

    The PROMIS Pain Interference consists of 4-items that assess the degree to which pain interferes with various aspects of life. Items are scored on a 1 ("Not at all") to 5 ("Very much") scale with a range of 4 - 20. Higher scores indicate greater pain interference

Secondary Outcome Measures

  1. Change in pain intensity based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There is one question that participants select 0 (no pain) - 10 (worst imaginable pain).

  2. Change in the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive function [Baseline, Week 24]

    There are 2 questions regarding cognitive function where participants select answers from not at all (1)-very mush (5) regarding cognitive function. There is a total of 10 points where higher scores mean higher cognitive function.

  3. Change in the physical function based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from without any difficulty (5) to unable to do (1). There are a total of 20 points where higher scores indicate higher physical function.

  4. Change in anxiety based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from never (1) to always (5). There are a total of 20 points where lower scores indicate lower levels of anxiety.

  5. Change in depression based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from never (1) to always (5). There are a total of 20 points where higher scores indicate higher levels of depression.

  6. Change in fatigue based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from not at all (1) to very much (5). There are a total of 20 points where higher scores indicate higher levels of fatigue.

  7. Change in sleep disturbance based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from. Question 1 participants will select from Very poor (5) to very good. Questions 2-4 participants will select from not all (5) to very much (1). There are a total of 20 points where higher scores indicate higher sleep disturbances.

  8. Change in ability to participate in social roles and activities based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from never (5) to always (1). There are a total of 20 points where lower scores indicate more difficulty participating in social roles.

  9. Change in pain interference based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 [Baseline, Week 24]

    There are 4 questions that participants will select from not at all (1) to very much (5). There are a total of 20 points where lower scores indicate less pain interference.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Chronic Lower Back pain (cLBP) defined by the National Institutes of Health (NIH) Task Force Report on Research Standards for Chronic Low Back Pain, (i.e., low back pain present at least six months, and present more than half of those days.)

  • Individuals must have a score of greater or equal to (≥) 50 on PROMIS Pain Interference.

Exclusion Criteria:
  • Current cancer related pain

  • Diagnosis of autoimmune disease

  • Unable to speak, write or read English

  • Visual or hearing difficulties

  • Pregnancy or breastfeeding

  • Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Michigan Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: Daniel Clauw, MD, University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniel Clauw, MD, Professor of Anesthesiology, University of Michigan
ClinicalTrials.gov Identifier:
NCT05843890
Other Study ID Numbers:
  • HUM00214375
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Daniel Clauw, MD, Professor of Anesthesiology, University of Michigan
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023